Fisetin is a plant compound in strawberries and apples studied as a longevity aid for clearing worn-out cells. Its most reliable effects are calming inflammation and oxidation; benefits for brain, bone, joint, and blood-vessel aging remain plausible but largely untested in people. Short human studies show it is well tolerated, mostly mild stomach upset. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | < 1.0 mg/L | Tracks systemic inflammation, fisetin's most plausible target |
| IL-6 | < 1.8 pg/mL | Marker of the inflammatory signaling fisetin aims to reduce |
| ALT / AST | ALT < 25 U/L (men), < 20 U/L (women) | Screens liver safety given hepatic metabolism of fisetin |
| eGFR / creatinine | eGFR > 90 mL/min/1.73m² | Confirms kidney handling capacity before/during use |
| Fasting glucose / HbA1c | Glucose 70–85 mg/dL; HbA1c < 5.4% | Contextualizes the speculative metabolic signal |
| CBC with platelets | Platelets 150–400 ×10⁹/L | Baseline before use given antiplatelet potential |
| Blood pressure | < 120/80 mmHg | Captures fisetin's modest blood-pressure-lowering effect |
Cadence: Liver, kidney, and inflammatory markers at ~4–8 weeks after starting, then every 6–12 months; blood pressure in the first weeks when combined with blood-pressure medication